Loading...
NYSE: OGN
Organon & Co.
Healthcare · Drug Manufacturers - General
Market Cap
$1.62B
52w High
$15.85
52w Low
$6.16
P/E
8.67
Volume
3.32M
Outstanding Shares
260.32M
Valuation Data Insufficient
The DCF model's fair value estimate is more than 3× the current stock price. This typically indicates unreliable model inputs — such as irregular cash flows or balance sheet distortions — rather than a genuine opportunity, so the valuation is not shown.
Company profile
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally.
CEOJoseph T. Morrissey Jr.
SectorHealthcare
IndustryDrug Manufacturers - General
Employees10,000
IPO dateMay 14, 2021
Valuation
Forward P/E—
EV/EBITDA7.87
Enterprise value$10.09B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth-5.34%
Gross margin53.59%▼6.78%vs FY2024
Operating margin20.01%▼10.92%vs FY2024
ROE24.87%▼86.42%vs FY2024
Analyst consensus
RatingBuy
Target price$6.50▲4.33%
3
Buy
2
Hold
3
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
View
EPS
Actual vs estimate by quarter
Q2FY25
ActualEst.
$1.00
$0.94
Q3FY25
ActualEst.
$1.01
$0.93
Q4FY25
ActualEst.
$0.63
$0.73
Q1FY26
Next Est.
—
Revenue
Actual vs estimate by quarter
Q2FY25
ActualEst.
$1.59B
$1.56B
Q3FY25
ActualEst.
$1.6B
$1.52B
Q4FY25
ActualEst.
$1.51B
$1.5B
Q1FY26
Next Est.
—